Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Validation of a respiratory symptom score from the Quality of Life-Bronchiectasis Questionnaire in adults with Mycobacterium avium complex lung disease.
Journal: Patient related outcome measures
Published: September 04, 2026
A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.
Journal: Pulmonary circulation
Published: October 17, 2025
Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.
Journal: Annals of the American Thoracic Society
Published: July 24, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Journal: The New England journal of medicine
Published: April 23, 2025
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.
Journal: The Lancet. Respiratory medicine
Published: March 11, 2025
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
Journal: American journal of respiratory and critical care medicine
Published: February 12, 2025
Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study.
Journal: Pulmonary therapy
Published: January 17, 2025
Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies.
Journal: Journal of patient-reported outcomes
Published: October 29, 2024
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.
Journal: ERJ open research
Published: February 15, 2024
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Journal: Respiratory research
Published: February 28, 2023
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Journal: Clinical pharmacokinetics
Published: May 26, 2022
Last Updated: 09/26/2026